Loading clinical trials...
Loading clinical trials...
A Post-marketing, Prospective, Open-label, Single-group, Multicentre Clinical Investigation to Evaluate the Effectiveness and Safety of a Medical Device Based on Non-cross-linked Hyaluronic Acid in Concentrations of 0.55% ("Electri") and 1.1%, 1.8%, or 2.2% ("XELA REDERM") (Diaco Biofarmaceutici S.r.l., Italy) for Improving the Aesthetic Appearance of Facial Skin.
Conditions
Interventions
XELA REDERM (non-cross-linked hyaluronic acid 1.1%, 1.8%, or 2.2%)
Electri (non-cross-linked hyaluronic acid 0.55%)
Locations
4
Poland
Provita Sp. z o.o.
Katowice, Poland
Ośrodek medyczny OSTEOMED s.c.
Krakow, Poland
Prime Clinic Sp. z o.o.
Warsaw, Poland
Institute Hyalual LLC
Kyiv, Ukraine
Start Date
March 30, 2021
Primary Completion Date
October 29, 2021
Completion Date
October 29, 2021
Last Updated
June 5, 2025
NCT07383766
NCT07151859
NCT07079397
NCT06206434
NCT07202117
NCT06259799
Lead Sponsor
Institute Hyalual GmbH
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions